tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Fulgent Genetics reports Q2 EPS 7c, consensus (18c)

Reports Q2 revenue $81.8M, consensus $76.21M. Ming Hsieh, chairperson of the board of directors and CEO, said, “In the first half of the year, we made good progress in growing revenue for our Laboratory Services business and in advancing our clinical trials for the Therapeutic Development business. I am pleased with the second quarter results and look forward to continued progress in the balance of 2025.”

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1